Zobrazeno 91 - 100
of 455
pro vyhledávání: '"Balázs Győrffy"'
Autor:
María Del Mar Noblejas-López, Sara Morcillo-García, Cristina Nieto-Jiménez, Miriam Nuncia-Cantarero, Balázs Győrffy, Eva M Galan-Moya, Atanasio Pandiella, Alberto Ocaña
Publikováno v:
PLoS ONE, Vol 13, Iss 11, p e0207776 (2018)
Regulation of transcription is a key process in cellular homeostasis. It depends on regulators that either repress or stimulate the transcription of genes, therefore controlling different biological functions. The Nuclear Receptor Corepressor 1 (NCOR
Externí odkaz:
https://doaj.org/article/38a077cf344646c396b1fd0ee35e5b34
Publikováno v:
Royal Society Open Science, Vol 5, Iss 12 (2018)
Background: Potential prognostic biomarker candidates for hepatocellular carcinoma (HCC) are abundant, but their generalizability is unexplored. We cross-validated markers of overall survival (OS) and vascular invasion in independent datasets. Method
Externí odkaz:
https://doaj.org/article/4dbe3480ec064d4eb5e832d016ef15a7
Autor:
Sandra Martínez-Canales, Francisco Cifuentes, Miguel López De Rodas Gregorio, Leticia Serrano-Oviedo, Eva María Galán-Moya, Eitan Amir, Atanasio Pandiella, Balázs Győrffy, Alberto Ocaña
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0175128 (2017)
BACKGROUND:Most patients with early stage triple negative breast cancer (TNBC) receive adjuvant chemotherapy. Activation of the immune system is associated with tumor response and may help identify TNBC with favorable outcome. METHODS:Gene expression
Externí odkaz:
https://doaj.org/article/1b582cb409bb425da74040e54c8825f7
Autor:
Tingting Jiang, Weiwei Shi, Vikram B Wali, Lőrinc S Pongor, Charles Li, Rosanna Lau, Balázs Győrffy, Richard P Lifton, William F Symmans, Lajos Pusztai, Christos Hatzis
Publikováno v:
PLoS Medicine, Vol 13, Iss 12, p e1002193 (2016)
BackgroundTriple negative breast cancer (TNBC) is a highly heterogeneous and aggressive disease, and although no effective targeted therapies are available to date, about one-third of patients with TNBC achieve pathologic complete response (pCR) from
Externí odkaz:
https://doaj.org/article/10e48ed9f47844dbabcb17db57e75d1b
Autor:
Van T. M. Nguyen, Iros Barozzi, Monica Faronato, Ylenia Lombardo, Jennifer H. Steel, Naina Patel, Philippa Darbre, Leandro Castellano, Balázs Győrffy, Laura Woodley, Alba Rodriguez-Meira, Darren K. Patten, Valentina Vircillo, Manikandan Periyasamy, Simak Ali, Gianmaria Frige, Saverio Minucci, R. Charles Coombes, Luca Magnani
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-1 (2019)
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Externí odkaz:
https://doaj.org/article/69915c68314f4c4da72a9fec0920fcd9
Autor:
Ylenia Perone, Aaron J. Farrugia, Alba Rodríguez-Meira, Balázs Győrffy, Charlotte Ion, Andrea Uggetti, Antonios Chronopoulos, Pasquale Marrazzo, Monica Faronato, Sami Shousha, Claire Davies, Jennifer H. Steel, Naina Patel, Armando del Rio Hernandez, Charles Coombes, Giancarlo Pruneri, Adrian Lim, Fernando Calvo, Luca Magnani
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-1 (2019)
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Externí odkaz:
https://doaj.org/article/fff95096dfe94029b18485fd44cda673
Autor:
Igor B. Roninson, Balázs Győrffy, Zachary T. Mack, Alexander A. Shtil, Michael S. Shtutman, Mengqian Chen, Eugenia V. Broude
Publikováno v:
Cells, Vol 8, Iss 8, p 821 (2019)
CDK8 and CDK19 Mediator kinases are transcriptional co-regulators implicated in several types of cancer. Small-molecule CDK8/19 inhibitors have recently entered or are entering clinical trials, starting with breast cancer and acute myeloid leukemia (
Externí odkaz:
https://doaj.org/article/bee188e8d9974110980495eb02bcfbec
Autor:
Otília Menyhart, Tatsuhiko Kakisaka, Lőrinc Sándor Pongor, Hiroyuki Uetake, Ajay Goel, Balázs Győrffy
Publikováno v:
Cancers, Vol 11, Iss 7, p 983 (2019)
Background: Numerous driver mutations have been identified in colorectal cancer (CRC), but their relevance to the development of targeted therapies remains elusive. The secondary effects of pathogenic driver mutations on downstream signaling pathways
Externí odkaz:
https://doaj.org/article/c95c5646cc06402f9b9064778078df63
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 11, p 2750 (2019)
Epithelial ovarian cancer (EOC) is one of the deadliest gynecological malignancies. Topotecan remains an essential tool in second-line therapy; even so, most patients develop resistance within a short period of time. We aimed to identify biomarkers o
Externí odkaz:
https://doaj.org/article/ec7a98fa69d14a27b5e1ee28a5333aa6
Autor:
Valerio Gelfo, Martina Mazzeschi, Giada Grilli, Moshit Lindzen, Spartaco Santi, Gabriele D’Uva, Balázs Győrffy, Andrea Ardizzoni, Yosef Yarden, Mattia Lauriola
Publikováno v:
Cancers, Vol 10, Iss 10, p 355 (2018)
Cetuximab (CTX) is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), commonly used to treat patients with metastatic colorectal cancer (mCRC). Unfortunately, objective remissions occur only in a minority of patients and are
Externí odkaz:
https://doaj.org/article/4e5803f27c6b4d12855f83e0ff3de709